ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca has signed three deals with small discovery firms. The drug company will work with Bind Therapeutics to develop an Accurin, a targeted nanomedicine, against a kinase inhibitor. Cambridge, Mass.-based Bind could receive up-front and milestone fees totaling more than $199 million. In another deal, Australia’s Alchemia will use its “versatile assembly on stable templates” chemistry to discover small molecules against multiple AstraZeneca targets. In return, AstraZeneca will pay an undisclosed amount up front and up to $240 million in milestone payments. And back home in the U.K., AstraZeneca is spending up to $75 million to access Horizon Discovery’s kinase target program for discovering cancer drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X